Many neurodegenerative disorders, such as Alzheimer's, Parkinson's and polyglutamine diseases, share a common pathogenic mechanism: the abnormal accumulation of disease-causing proteins, due to either the mutant protein's resistance to degradation or overexpression of the wild-type protein. We have developed a strategy to identify therapeutic entry points for such neurodegenerative disorders by screening for genetic networks that influence the levels of disease-driving proteins. We applied this approach, which integrates parallel cell-based and Drosophila genetic screens, to spinocerebellar ataxia type 1 (SCA1), a disease caused by expansion of a polyglutamine tract in ataxin 1 (ATXN1). Our approach revealed that downregulation of several components of the RAS-MAPK-MSK1 pathway decreases ATXN1 levels and suppresses neurodegeneration in Drosophila and mice. Importantly, pharmacological inhibitors of components of this pathway also decrease ATXN1 levels, suggesting that these components represent new therapeutic targets in mitigating SCA1. Collectively, these data reveal new therapeutic entry points for SCA1 and provide a proof-of-principle for tackling other classes of intractable neurodegenerative diseases.
The increasing prevalence of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease in the ageing population is one of our most pressing public health issues 1, 2 . There is no diseasemodifying treatment for most of these disorders, and therapies that do exist target the late stages of disease, when pathogenesis is already advanced and the symptomatic relief is partial and short-lived 3, 4 . It would clearly be preferable to delay the onset of symptoms, slow disease progression or reverse the course of the disease, but to do this probably requires us to address earlier stages of pathogenesis.
Fortunately, two decades of research on inherited neurodegenerative diseases (Huntington's disease, the spinocerebellar ataxias and inherited forms of Alzheimer's disease and Parkinson's disease) have revealed certain pathogenic commonalities at the molecular level 5 . For instance, although the respective disease-causing proteins (HTT, ataxins, APP and a-synuclein) and neuronal populations vulnerable to their toxicity are distinct in each disorder [6] [7] [8] , each of these diseases involves the toxic accumulation of the mutant protein; in some cases too much of the wild-type protein is also toxic [9] [10] [11] . Importantly, animal models have shown that decreasing the accumulation of the normal or mutant proteins, usually by genetic manipulation, can reverse disease phenotypes [12] [13] [14] [15] [16] [17] [18] . We therefore set out to identify druggable targets that modulate the level of a neurodegenerative disease-causing protein: glutamine-expanded ATXN1, which is mutated in SCA1.
To exploit the unbiased, functional nature of genetic screens and compensate for the weaknesses inherent in any given model system, we developed a cross-species strategy: complementary forward genetic screens that targeted the levels of glutamine-expanded human ATXN1 in a SCA1 Drosophila model and in a human cell model for SCA1. We chose to use modulation of ATXN1 levels as a proof-of-principle for this strategy for three reasons: (1) the severity of neurodegeneration in SCA1 correlates with the levels of the mutant ATXN1 protein; (2) overexpression of wild-type ATXN1 leads to neurodegeneration; and (3) the pathogenic mechanisms underlying SCA1 are well characterized 19 . Our genetic screening approach revealed that multiple components of the RAS-MAPK-MSK1 pathway influence ATXN1 levels in Drosophila and human cells. We then validated these results using SCA1 mouse models and further found that pharmacological targeting of this pathway also reduces ATXN1 levels.
Strategy to identify regulators of ATXN1 levels
To identify regulators of ATXN1 levels in human cells of neural lineage, we engineered a human medulloblastoma-derived cell line with a transgene encoding a glutamine-expanded ATXN1 fused with monomeric red fluorescent protein (mRFP-ATXN1(82Q)). To distinguish modifiers regulating ATXN1 protein levels from those affecting transgene transcription, we placed an internal ribosomal entry site (IRES) followed by yellow fluorescent protein (YFP) downstream of the ATXN1 fusion protein (mRFP-ATXN1(82Q)-IRES-YFP). The ratio of mRFP to YFP fluorescence by flow cytometric analysis thus serves as a read-out for genes that regulate mRFP-ATXN1(82Q) protein levels while controlling for fluctuations in transcription of the transgene (Fig. 1a) .
We focused on interrogating human kinases, because (1) phosphorylation is crucial to ATXN1 toxicity 20 ; and (2) many kinases are targeted (or amenable to targeting by) pharmacological agents 21 . We used this cell system to test individually the effects of short interfering RNAs (siRNAs) targeting every known human kinase and kinase-like gene (1,908 siRNAs, 636 genes; tests performed in triplicate) on ATXN1 levels. We selected for further study 181 siRNAs that reduced the ratio of mRFP to YFP fluorescence by two standard deviations from the screen-wide mean (Fig. 1b) . siRNAs from these primary hits were transfected independently in ATXN1(82Q) cells for confirmation and were tested in parallel with a control reporter line (cells encoding mRFP-IRES-YFP lacking the ATXN1 fusion) to eliminate false-positive hits that targeted mRFP. These analyses validated 50 siRNA candidates (corresponding to 45 genes) that reduce ATXN1(82Q) levels (Supplementary Table 1 ).
In parallel, we performed a genetic screen in a Drosophila SCA1 model expressing human ATXN1(82Q), in which fruitflies develop an external eye phenotype in response to ATXN1 toxicity 22 (Fig. 1c) . We screened a total of 704 alleles (including inducible short hairpin RNAs (shRNAs) and loss-of-function mutations) corresponding to 337 kinase-encoding Drosophila genes for those that would modulate mutant ATXN1 levels. We then performed retinal sections to determine whether these modulators of the external eye phenotype also improved photoreceptor integrity. The morphological and histological phenotype assessment yielded 51 alleles (corresponding to 49 genes) that suppressed ATXN1(82Q) toxicity in vivo (Supplementary Table 2) .
These Drosophila and human-cell-based screens revealed ten human modifier genes that reduce both ATXN1 levels and ATXN1-induced toxicity (IGF1R, ULK3, WNK4, BUB1, MSK1 (also known as RPS6KA5), MEK2 (also known as MAP2K2), MEK3 (also known as MAP2K3), MEK6 (also known as MAP2K6), ERK1 (also known as MAPK3) and ERK2 (also known as MAPK1)) and that correspond to eight modifiers in Drosophila (CG3837 (also known as Sdr), CG8866, CG7177 (also known as Wnk), BubR1, JIL-1, Dsor1, lic and rl) (Figs 1c, d , 2a-c and Supplementary Fig. 1 ). We selected these genes for further characterization.
Reducing MAPK signalling decreases ATXN1
Network analysis of the hits from human cells and Drosophila revealed that the MAPK cascade is the most enriched pathway in each screen (Supplementary Table 3 ). In addition, analysis of the ten common genes shows that the MAPK cascade is the most highly represented signalling pathway. In fact, six of the ten shared hits (ERK1, ERK2, MEK2, MEK3, MEK6 and MSK1) are canonical components of this pathway, and WNK4 and IGF1R are known to regulate it [23] [24] [25] (Fig. 2e , Supplementary Table 4 and Supplementary Fig. 1d ). This pathway is a component of a cell-signalling cascade that also includes RAS, RAF and MEK and that can be activated by a variety of mitogens, growth factors and receptor tyrosine kinases 26, 27 ( Supplementary Fig. 1d ). To validate the effects of the MAPK pathway hits in the central nervous system of an intact animal, we used a motor performance assay that measures climbing ability in fruitflies. Expression of ATXN1(82Q) in the Drosophila central nervous system leads to progressive impairment in motor performance 28 . We found that decreased levels of the Drosophila homologues of MEK (DSOR1), ERK1/2 (RL) and MSK1 (JIL-1) suppressed ATXN1(82Q)-induced motor deficits and improved lifespan in ATXN1(82Q) flies (Fig. 2d) .
We next sought to determine whether other upstream components of the MAPK pathway modulate ATXN1 toxicity. We found that decreased levels of the Drosophila homologues of farnesyltransferase (FNTB), GRB2, SOS, HRAS, RRAS and RAF suppress the ATXN1(82Q)-induced external eye phenotype as well as photoreceptor degeneration ( Fig. 3a and Supplementary Fig. 2a, b) . Decreasing the levels of the Drosophila homologues of FNTA, SOS, HRAS and RAF improved the ATXN1(82Q)-induced motor and lifespan phenotypes ( Fig. 3b and Supplementary Fig. 3 ). In addition, activation of MAPKs via a constitutively active form of Drosophila RAS (dRAS-V12) exacerbated the ATXN1(82Q)-induced eye degeneration ( Supplementary Fig. 4a ).
Prompted by this genetic evidence that the RAS-MAPK-MSK pathway governs ATXN1(82Q)-induced phenotypes, we investigated the ability of this pathway to modulate ATXN1(82Q) protein levels. We found that reducing the levels of HRAS and FNTA led to a decrease in ATXN1 levels in human cells (Fig. 3c, d , Supplementary  Fig. 2c and Supplementary Fig. 5 ). Furthermore, we confirmed that decreasing the levels of any of the two functionally conserved RAS homologues in Drosophila (dRAS (also known as RAS85D) and RAS64B) also decreased the levels of ATXN1(82Q) in vivo (Fig. 3e) . Reducing the levels of the RAS/MAPK genes also decreased ATXN1(30Q) levels in cells and suppressed ATXN1(30Q)-induced toxicity in Drosophila ( Supplementary Fig. 6 ).
In summary, the genetic screen in cells and fruitflies unveiled the RAS/MAPK pathway as critical for modulating ATXN1 levels (Fig. 3f ).
MSK1 stabilizes ATXN1 by phosphorylating S776
Building on our previous discovery that ATXN1 levels are highly sensitive to phosphorylation at residue S776 (mutation of serine to alanine decreases both ATXN1 stability and toxicity) 20 ,29 , we investigated whether the MAPK pathway kinases (MEK, ERK and MSK1) RESEARCH ARTICLE recovered in our screens phosphorylate ATXN1 at S776. This residue falls within the consensus phosphorylation sequence RXXS (in which X denotes any residue) that is conserved in ATXN1 homologues (Fig. 4a ). Most MAPK proteins are known to prefer PX(S/T)P (in which brackets denote alternative residues), so we excluded MEK and ERK. Instead, we focused on MSK1, which is known to prefer the consensus sequence RXXS 30 . To determine whether MSK1 directly phosphorylates ATXN1 at S776, we conducted in vitro kinase assays with purified MSK1 and glutathione-S-transferase-ATXN1(82Q) (GST-ATXN1(82Q)). We immunoblotted with anti-phospho-S776 ATXN1 antibody 20 and found that the antibody detected robust phospho-S776 ATXN1 signal upon addition of MSK1 (Fig. 4b) . Furthermore, MSK1 can phosphorylate both the mutant GST-ATXN1(82Q) and the wild-type GST-ATXN1(30Q) (Fig. 4b) . It is noteworthy that RSK1 (also known as RPS6KA1) and RSK2 (also known as RPS6KA3), two other kinases that share the RXXS consensus sequence and are also downstream of the MAPK pathway 30 , failed to phosphorylate the S776 site (Supplementary Fig. 7a-c) .
We next investigated whether the observed effect of MSK1 on ATXN1 stability is mediated by S776 phosphorylation in vivo. We found increased levels of ATXN1(82Q) upon coexpression with Msk1 in mouse Neuro2A cells (Fig. 4c) . This increase was dependent on S776 phosphorylation, because Msk1 did not increase the levels of ATXN1(82Q, S776A) (Fig. 4c) . We also performed cerebellar fractionation assays from wild-type mouse brains and examined whether Msk1 was enriched in the fractions containing S776 phosphorylation activity. As shown in Supplementary Fig. 8a , Msk1 was enriched in the fractions containing peak S776-phosphorylating activity. To confirm whether endogenous Msk1 from neural lineages contributes to ATXN1 phosphorylation, we immunodepleted Msk1 from mouse cerebellar extracts and found that reduction of Msk1 significantly 
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decreased S776 phosphorylation of bacterially purified ATXN1 compared to non-depleted extracts ( Fig. 4d and Supplementary Fig. 7d ).
Having established the role of MSK1 in phosphorylating a serine critical for modulating ATXN1 stability, we investigated the effects of MSK1 on ATXN1 level in Drosophila. We found that reducing the level of the Drosophila homologue of MSK1 decreased the steady-state level of ATXN1(82Q) in vivo (Fig. 4e) .
In summary, the data from the cell-based screen, biochemical studies and genetic interactions strongly suggest that MSK1 phosphorylates ATXN1 and regulates its stability. Furthermore, we tested whether the components upstream of MSK1 in the MAPK pathway also affect ATXN1 S776 phosphorylation. Western blot analysis showed that knockdown of RAS, FNTA and MEK significantly decreases S776 phosphorylation, whereas constitutive activation of RAS and MEK1 markedly increases its phosphorylation and stability ( Supplementary  Fig. 4b, c and Supplementary Fig. 5 ).
Together, these results suggest that the RAS-MAPK-MSK1 pathway regulates ATXN1 stability through S776 phosphorylation.
Inhibition of MAPK pathway decreases ATXN1
Our data indicate that genetic inhibition of the MAPK pathway reduces ATXN1 levels and phenotypes. To evaluate the MAPK pathway as a potential therapeutic target for SCA1, we investigated whether pharmacological inhibition of the MAPK pathway (Fig. 3f) (Fig. 5a ). The MSK1 inhibitors H89 and Ro-31-8220 33 also decreased the levels of ATXN1(82Q) (Fig. 5a ). To examine this reduction in a more physiologically relevant system, we tested whether inhibiting MAPK or MSK1 signalling affected Atxn1(82Q) abundance in the context of cerebellar slice cultures from SCA1 (82Q) knock-in mice 34 . Western blot analysis (Fig. 5b, c) showed that inhibition of Mek1/2 or Msk1 (by addition of PD184352 and Ro-31-8220, respectively) in cerebellar slice cultures decreased the levels of mutant Atxn1.
Together with the genetic data, these results strongly support the hypothesis that the MAPK/MSK1 pathway regulates ATXN1 levels. These findings also validate the genetic screen strategy and provide evidence that ATXN1 levels can be modulated pharmacologically.
Reducing MSK1 rescues degeneration in SCA1 mice
We next sought to test the genetic interaction between MSK1 and ATXN1 in mice. For this we used Atxn1(154Q) knock-in mice (Atxn1
), which bear 154 CAG repeats in the endogenous mouse locus and 
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Age ( (Fig. 6a, b ). Atxn1 154Q/1 mice develop a motor phenotype that can be quantified after 9 weeks of age using a rotarod test. Drosophila has only one Msk gene (JIL-1), but mice have two paralogues: Msk1 and Msk2. To account for potential genetic redundancy, we investigated the effect on the Atxn1(154Q)-induced phenotype of decreasing both genes simultaneously. The Atxn1 154Q/1 Msk1 1/2 Msk2 1/2 animals showed significantly better rotarod performance than their Atxn1 154Q/1 littermates (P 5 0.027, Fig. 6c) .
Next, we assessed the potential effect of decreasing Msk on Purkinje cell degeneration. Because Purkinje cell loss takes over 7-8 months to manifest in the Atxn1 154Q/1 mice, we resorted to another SCA1 mouse model that expresses ATXN1(82Q) using the Pcp2 promoter (B05 transgenic mice) and develops severe Purkinje cell degeneration after 12 weeks 38 . We found that eliminating one copy of mouse Msk1 partially suppressed this Purkinje-cell-loss phenotype. Simultaneous elimination of one copy of Msk1 and Msk2 (B05
) also suppressed Purkinje cell loss (Fig. 6d) (Supplementary Fig. 8b ).
Discussion
Here we combine cross-species genetic screens and validation in human, mouse and Drosophila systems to identify previously unappreciated modulators of the steady-state levels of a neurodegeneration-causing protein. Two key discoveries highlight the power and reliability of this screening strategy. First, several modulators of ATXN1 levels belong to a single pathway, the RAS-MAPK-MSK1 signalling pathway. The functional relationship between the newly identified ATXN1 modulators underscores the validity of the approach and distinguishes these findings from screens done in one system whereby the large number of hits often precludes identifying the true positives and linking them in a functional pathway. Second, the screening approach and subsequent characterization revealed a direct biochemical mechanism governing ATXN1 levels (ATXN1 S776 phosphorylation by MSK1) as well as upstream regulators of ATXN1 abundance. The identification of direct (MSK1) and upstream (RAS and MAPK) regulators of ATXN1 levels provides several entry points for developing strategies for therapeutic intervention for SCA1.
Identifying multiple targets that can decrease disease protein levels is important for several reasons. First, the discovery of multiple therapeutic entry points counterbalances the frequent attrition of therapeutic targets during drug development. Second, the discovery of multiple targets enables the development of combination strategies (via multiple inhibitors or inhibitors with activity towards multiple targets 39 ) to balance symptom mitigation and side effects. We note that, in the case of ATXN1, S776 can be phosphorylated by protein kinase A 29 . The discovery that MSK1 also phosphorylates ATXN1 at S776 raises the possibility that mild-to-modest inhibition of both kinases might be more effective than severe inhibition of either. Of course, the availability of several additional modulators of ATXN1 levels in the RAS-MAPK-MSK1 pathway now provides further opportunity to explore the development of combination therapeutics.
Previous efforts aimed at developing unbiased screens for the discovery of therapeutic targets for neurodegenerative diseases have focused on protein aggregation or suppression of neuronal cell death 40 . The strategy we used in this study focuses on targeting an earlier event in disease pathogenesis: decreasing the levels of the disease-causing protein. Genetic data in humans and animal models provide evidence that increased levels of either the mutant or the normal proteins are at the root of the pathogenesis of several neurodegenerative diseases. For example, expanded polyglutamine tracts stabilize the disease proteins in Huntington's disease and spinocerebellar ataxias [41] [42] [43] , whereas increased levels of wild-type APP and a-synuclein due to genomic duplications and triplications cause Alzheimer's disease and Parkinson's disease, respectively [9] [10] [11] . Therefore, targeting an early event in pathogenesis could potentially delay the disease onset for this class of from three independent experiments. *P , 0.05, **P , 0.01, ***P , 0.001, Student's t-test. DMSO, dimethylsulphoxide.
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disorders. Indeed, a key challenge in Alzheimer's and Parkinson's diseases has been our limited understanding of how the stability of APP and a-synuclein is controlled. An unbiased forward genetic screen using independent and complementary assays to decrease the levels of APP and a-synuclein is likely to yield a variety of targets that might change the landscape of therapeutic development for these diseases. Furthermore, applying this approach at a genome-wide scale would enable us to discover other possible therapeutic targets. We note that cross-species comparative genomics (messenger RNA expression profiling and gene copy number) has been recently used to discover new pathogenic pathways in the cancer field 44 . We believe that this study provides a proofof-principle for addressing other neurodegenerative diseases using a similar conceptual strategy.
METHODS SUMMARY
The Daoy mRFP-ATXN1(82Q)-IRES-YFP stable cell line was generated by cloning into pHAGE lentiviral vector, then selected with puromycin and run through AriaII (BD Biosciences) for selection of single cells that showed expression of mRFP and YFP. For the kinase siRNA screen, cells were split into 96-well plates and each siRNA (kinase siRNA library from Invitrogen) was transfected into corresponding wells. After 72 h incubation, the cells were analysed by flow cytometry (LSR II, BD Biosciences). Statistical analyses for primary and secondary human cell screens were performed using JMP software from SAS. For the Drosophila genetic screen, we used the GMR . ATXN1(82Q) fly line 22 . In total, 704 kinase RNA interference or loss-of-function alleles were obtained from VDRC, Bloomington and Harvard repositories. Scanning electron microscopy and paraffin sections of the retina were performed as previously described 22 . All Drosophila genotypes are indicated in Supplementary Information. The Drosophila climbing assay was done as previously described 28 . For kinase assay, 1 mg of bacterially expressed and purified GST-ATXN1(82Q) or GST-ATXN1(30Q) and 100 ng of active MSK1 (Invitrogen) were incubated in kinase reaction buffer (50 mM Tris-HCl, pH 7.6, 150 mM NaCl, 10 mM MgCl 2 , 1 mM dithiothreitol) with phosphatase inhibitor (Roche) and 30 mM ATP (Invitrogen) for 30 min at 30 uC. For mice cerebella sections, cerebellum from SCA1 (82Q) knock-in mice 34 at postnatal day 11 were embedded in a 2% agarose/Gey's balanced salt solution containing 1 mM kynurenic acid (GBSSK) solution and sectioned at 350 mm as described 45 . Slices were cultured in collagen coated membrane inserts in cerebellar slice culture media. Atxn1 154Q/135 or ATXN1(82Q) (B05) 38 and Msk1 1/2 Msk2 1/236,37 mice were crossed to obtain mice with appropriate genotypes. Rotarod analysis was performed as previously described 46 . Purkinje cell pathology was observed by immunofluorescence staining of cerebellar sections using anti-calbindin antibody (Sigma) and imaged by a Zeiss LSM 710 confocal microscope 47 .
Full Methods and any associated references are available in the online version of the paper. RESEARCH ARTICLE
